C4 Therapeutics Announces Promising Phase 1 Trial Results for Cemsidomide in Relapsed/Refractory Multiple Myeloma Treatment
Reuters
Sep 23, 2025
C4 <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Promising Phase 1 Trial Results for Cemsidomide in Relapsed/Refractory Multiple Myeloma Treatment
C4 Therapeutics, Inc. has announced the results from its Phase 1 clinical trial of cemsidomide, an orally bioavailable IKZF1/3 degrader, in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma. These results were presented at the International Myeloma Society Annual Meeting. The trial demonstrated a 50% overall response rate at the highest cemsidomide dose level of 100 µg, and a 40% response rate at the 75 µg dose level in a heavily pre-treated patient population. The median duration of response was reported as 9.3 months across dose levels, though it has not been reached at the two highest doses. The safety profile was favorable, with no discontinuations related to cemsidomide and few dose reductions. Upcoming milestones include aligning with the FDA on the Phase 2 dose recommendation by the end of 2025 and initiating further trials in 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-042245), on September 22, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.